Precision BioSciences Appoints Alex Kelly as Chief Financial Officer

DURHAM, N.C. --(BUSINESS WIRE)--May 27, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced the appointment of Alex Kelly as Chief

Precision BioSciences to Participate in the Jefferies Virtual Healthcare Conference

DURHAM, N.C. --(BUSINESS WIRE)--May 26, 2021-- Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Derek Jantz , Ph.D., Chief Scientific

Precision BioSciences to Present Data from its First Generation CD19 Allogeneic CAR T Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 American Society of Clinical Oncology Meeting

Precision to Provide PBCAR0191 Update via Hosted Conference Call and Webcast on Friday, June 4, 2021 DURHAM, N.C. --(BUSINESS WIRE)--May 19, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies,

Precision BioSciences Reports First Quarter and 2021 Financial Results and Provides Business Update

- Reacquired Global Development and Commercialization Rights to all Servier Partnered CAR T Programs, Including PBCAR0191 and PBCAR19B Stealth Cell - Expect to Present Updated PBCAR0191 Data in June at ASCO 2021 - Plan to Initiate Phase 1 Study of PBCAR19B Stealth Cell in Patients with R/R NHL by

New Preclinical Data Presented at the 2021 American Society of Genetic & Cell Therapy Annual Meeting Highlights Precision BioSciences’ ARCUS In Vivo Genome Editing

Results Show Promising Gene Editing Approach for Transthyretin Amyloidosis DURHAM, N.C. --(BUSINESS WIRE)--May 11, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome

Precision BioSciences to Report First Quarter 2021 Financial Results on May 13, 2021

DURHAM, N.C. --(BUSINESS WIRE)--May 6, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced it will publish first quarter 2021 financial

Precision BioSciences Announces Paper Presentation at the Association for Research in Vision and Ophthalmology 2021 Annual Meeting

  Preclinical Research with ARCUS Genome Editing Rejuvenated Rod Photoreceptor Structure and Function in a Transgenic Pig Model of Human Blindness DURHAM, N.C. --(BUSINESS WIRE)--May 3, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic

Precision BioSciences Announces Poster Presentation at the Upcoming American Society of Gene & Cell Therapy Annual Meeting

Preclinical Study Shows ARCUS Genome Editing May Be a Promising Approach for the Treatment of Transthyretin Amyloidosis DURHAM, N.C. --(BUSINESS WIRE)--Apr. 27, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene

Precision BioSciences Appoints Renowned Hematologist Alan List, M.D. as Chief Medical Officer

DURHAM, N.C. --(BUSINESS WIRE)--Apr. 15, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Alan List , M.D.

Precision BioSciences Reacquires Global Rights to its Allogeneic CAR T Programs

- Precision Reacquires from Servier its Global Development and Commercialization Rights and Control of All Partnered CAR T Programs, Including PBCAR0191 and PBCAR19B Stealth Cell - Servier Eligible to Receive Milestones and Royalties Based on Program Success - Precision to Host Conference Call and

Precision BioSciences Appoints Stanley R. Frankel, M.D. to Board of Directors

DURHAM, N.C. --(BUSINESS WIRE)--Apr. 12, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced that Stanley R. Frankel , M.D.

Precision BioSciences to Participate in the Truist Securities 2021 Life Sciences Virtual Series

DURHAM, N.C. --(BUSINESS WIRE)--Apr. 9, 2021-- Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Derek Jantz , Ph.D., Chief Scientific

Precision BioSciences Announces CEO Transition Plan

Begins Search for Next Chief Executive Officer DURHAM, N.C., April 06, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today

Precision BioSciences to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Day

DURHAM, N.C., March 29, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced it will participate in the Guggenheim

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update

Established in vivo genome editing research collaboration and exclusive license agreement with Eli Lilly Reported interim data from Phase 1/2a study of PBCAR0191; updated interim data expected by mid-year 2021 Interim data releases expected from PBCAR269A and PBCAR20A in 2021 Received FDA